Corneal collagen crosslinking for the treatment of progressive keratoconus

The aim of this HTA short report is to evaluate the efficacy, safety, cost-effectiveness and budget impact of corneal collagen crosslinking (CXL) compared to sham or no treatment in patients with progressive keratoconus.

Last modification 30.04.2021

Top of page

Contact

Federal Office of Public Health FOPH
Health insurance benefits Division
Health Technology Assessment Section
Schwarzenburgstrasse 157
3003 Bern
Switzerland
Tel. +41 58 469 17 33
E-mail

Print contact

https://www.bag.admin.ch/content/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/crosslinking.html